Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial
Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease. Fucoidans are reportedly effective in treating AD; however, their clinical efficacy requires further exploration. This study aimed to investigate the clinical efficacy of low-molecular-weight fucoidan (LMF) supplementation in p...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | International Journal of Food Properties |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/10942912.2023.2292472 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846163926374416384 |
|---|---|
| author | Huei-Ling Shih Pin-Han Wang I-Hsin Shih Sindy Hu Jr-Rung Lin Pei-Yu Hsu Sien-Hung Yang |
| author_facet | Huei-Ling Shih Pin-Han Wang I-Hsin Shih Sindy Hu Jr-Rung Lin Pei-Yu Hsu Sien-Hung Yang |
| author_sort | Huei-Ling Shih |
| collection | DOAJ |
| description | Atopic dermatitis (AD) is a chronic recurrent inflammatory skin disease. Fucoidans are reportedly effective in treating AD; however, their clinical efficacy requires further exploration. This study aimed to investigate the clinical efficacy of low-molecular-weight fucoidan (LMF) supplementation in patients with AD and reveal the underlying mechanism of its effects; this is a randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to a study or control group to receive conventional AD therapy with oral supplementation of either LMF or placebo for 12 weeks. Symptom severity was measured by the SCORing Atopic Dermatitis (SCORAD) index. Each participant used a diary to record daily medication use. Blood samples were collected at three time points for assessing AD-related cytokines, immunoglobulin E (IgE), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, the percentage of eosinophils, and biochemical profiles of hepatic and renal functions. The study group showed significant symptom relief, whereas the control group showed no significant improvements. The frequency of steroid ointment application significantly decreased, and the frequency of oral antihistamine use decreased in the study group, whereas no significant changes were observed in the control group. The AD-related immune parameters serum IgE, eosinophils, CD8+ T cells, interferon-γ (IFN-γ), ESR, and CRP significantly decreased in the study group but not the control group. There were no severe adverse events in either group. This study is the first to demonstrate the effectiveness and safety of LMF as a supplemental therapy for patients with AD via its anti-inflammatory activity. |
| format | Article |
| id | doaj-art-a33d08b2be1b4b7f9e853ea2a7f09753 |
| institution | Kabale University |
| issn | 1094-2912 1532-2386 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | International Journal of Food Properties |
| spelling | doaj-art-a33d08b2be1b4b7f9e853ea2a7f097532024-11-18T20:58:53ZengTaylor & Francis GroupInternational Journal of Food Properties1094-29121532-23862024-12-012718810510.1080/10942912.2023.2292472Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trialHuei-Ling Shih0Pin-Han Wang1I-Hsin Shih2Sindy Hu3Jr-Rung Lin4Pei-Yu Hsu5Sien-Hung Yang6Division of Chinese Internal Medicine, Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of Chinese Internal Medicine, Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, TaiwanDepartment of Dermatology, Chang Gung Memorial Hospital, Taoyuan, TaiwanDepartment of Dermatology, Chang Gung Memorial Hospital, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Graduate Institute of Clinical Medicine, Chang Gung University, Taoyuan, TaiwanDivision of Chinese Internal Medicine, Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, TaiwanDivision of Chinese Internal Medicine, Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Taoyuan, TaiwanAtopic dermatitis (AD) is a chronic recurrent inflammatory skin disease. Fucoidans are reportedly effective in treating AD; however, their clinical efficacy requires further exploration. This study aimed to investigate the clinical efficacy of low-molecular-weight fucoidan (LMF) supplementation in patients with AD and reveal the underlying mechanism of its effects; this is a randomized, double-blind, placebo-controlled trial. Participants were randomly assigned to a study or control group to receive conventional AD therapy with oral supplementation of either LMF or placebo for 12 weeks. Symptom severity was measured by the SCORing Atopic Dermatitis (SCORAD) index. Each participant used a diary to record daily medication use. Blood samples were collected at three time points for assessing AD-related cytokines, immunoglobulin E (IgE), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), white blood cell (WBC) count, the percentage of eosinophils, and biochemical profiles of hepatic and renal functions. The study group showed significant symptom relief, whereas the control group showed no significant improvements. The frequency of steroid ointment application significantly decreased, and the frequency of oral antihistamine use decreased in the study group, whereas no significant changes were observed in the control group. The AD-related immune parameters serum IgE, eosinophils, CD8+ T cells, interferon-γ (IFN-γ), ESR, and CRP significantly decreased in the study group but not the control group. There were no severe adverse events in either group. This study is the first to demonstrate the effectiveness and safety of LMF as a supplemental therapy for patients with AD via its anti-inflammatory activity.https://www.tandfonline.com/doi/10.1080/10942912.2023.2292472Low-molecular-weight fucoidanAtopic dermatitisSCORADinflammationIFN-γ |
| spellingShingle | Huei-Ling Shih Pin-Han Wang I-Hsin Shih Sindy Hu Jr-Rung Lin Pei-Yu Hsu Sien-Hung Yang Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial International Journal of Food Properties Low-molecular-weight fucoidan Atopic dermatitis SCORAD inflammation IFN-γ |
| title | Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial |
| title_full | Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial |
| title_fullStr | Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial |
| title_full_unstemmed | Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial |
| title_short | Efficacy and anti-inflammatory properties of low-molecular-weight fucoidan in patients with atopic dermatitis: a randomized double-blinded placebo-controlled trial |
| title_sort | efficacy and anti inflammatory properties of low molecular weight fucoidan in patients with atopic dermatitis a randomized double blinded placebo controlled trial |
| topic | Low-molecular-weight fucoidan Atopic dermatitis SCORAD inflammation IFN-γ |
| url | https://www.tandfonline.com/doi/10.1080/10942912.2023.2292472 |
| work_keys_str_mv | AT hueilingshih efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial AT pinhanwang efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial AT ihsinshih efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial AT sindyhu efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial AT jrrunglin efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial AT peiyuhsu efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial AT sienhungyang efficacyandantiinflammatorypropertiesoflowmolecularweightfucoidaninpatientswithatopicdermatitisarandomizeddoubleblindedplacebocontrolledtrial |